Zachary Sax, DPM
Foot & Ankle Surgery · Chestnut Hill, MANPI 1669904140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $902 of the $1,109 with a category attached, or 81.3%. 13 manufacturers reported payments, led by Ossio Inc at 27.6% of the total. Reporting peaked in 2024 at $405 and has fallen 88.1% since, to $48 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in MA, where the typical reported total is $1,627.
Across 30 payments — averaging $36.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ossio Inc$307
- Medical Device Business Services, Inc.$207
- AbbVie$114
- Smith+Nephew$113
- Nevro Corp.$80
- Bioventus LLC$59
- plus $229 from 7 others
What the payments were for
- Food & beverage$90281%
- Education$20719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ossio Inc | 1 | $307 |
| Medical Device Business Services, Inc. | 2 | $207 |
| AbbVie | 2 | $114 |
| Smith+Nephew | 7 | $113 |
| Nevro Corp. | 3 | $80 |
| Bioventus LLC | 3 | $59 |
| Orthofix Medical, Inc. | 3 | $49 |
| Sebela Pharmaceuticals Inc. | 3 | $48 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Vertex | 1 | $32 |
| Convatec Inc. | 1 | $24 |
| IBSA Pharma Inc. | 1 | $17 |
| Paragon 28, Inc. | 1 | $16 |
How this compares
$1,109 in reported general payments places this provider in the 40th percentile of 122 foot & ankle surgery providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 47 | $2,072 |
| Ammonium Lactate | 64 | $732 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $382 |
| Mupirocin | 47 | $379 |
| Terbinafine Hcl | 18 | $154 |
| Naproxen | 23 | $98 |
| Cephalexin | 11 | $54 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Chestnut Hill
- Harry SchneiderCambridge$174K
- Craig LareauSpringfield$115K
- David SipalaBrighton$94K
- Philip BasileCambridge$90K
- Michael SgangaNatick$90K
- Joseph FleckNorth Chelmsford$35K
- Michael SkoniecznyPlymouth$33K
- Richard BakerHyannis$16K
- Mark SlovenkaiWaltham$14K
- Jaeyoung KimBoston$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.